Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Sell rating on Sarepta Therapeutics (SRPT – Research Report). The associated ...

Shares of Sarepta (SRPT) are down this morning, potentially due to the latest FDA Adverse Event Reporting System update on Elevidys, which ...

The positive results from the second part of the EMBARK trial contrast with findings from one-year post treatment, which did ...

Top-line Phase 3 trial data show ambulatory boys with Duchenne continued with motor improvements two years after a single ...

In year two of the trial, Elevidys demonstrated statistically significant and clinically improvements across three key ...

Roche and Sarepta Therapeutics have shared positive top-line results from a late-stage study of Elevidys (delandistrogene ...

The gene therapy improved motor functions in children with Duchenne muscular dystrophy two years after treatment ...

Securities maintained their positive outlook on Sarepta Therapeutics (NASDAQ:SRPT), reiterating an Outperform rating and a ...

BMO Capital Markets sustained a favorable outlook on Sarepta Therapeutics (NASDAQ:SRPT), maintaining an Outperform rating and a $200.00 price target for the company's shares. Currently trading at $116 ...

Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement ...

Roche has reported positive topline outcomes from the second year of the multinational Phase III EMBARK trial of Elevidys for ...

While the last decade has brought considerable progress for patients with DMD, substantial unmet need remains. Several ...